Literature DB >> 8067143

[The spread of hepatitis C markers among the population of regions of Russia and Central Asia].

T L Iashina, M O Favorov, I V Shakhgil'dian, D M Iarasheva, O I Nazarova, E N Derevianko, M I Ommadova, G G Onishchenko, Y Watanabe, K Nishioka.   

Abstract

A total of 2,217 blood serum samples taken from the population of some regions of the former USSR were studied for the presence of antibodies to hepatitis C virus (HCV) with the use of a commercial enzyme immunoassay system (obtained from Ortho, Japan). Perceptible changes in the detection rate of these antibodies throughout the territory of the former USSR were established. Most frequently anti-HCV antibodies were detected among the population of the republics of Central Asia (5.3-2.9%), as well as Tuva and Yakutia (2.5-3.0%), their lowest detection rate was in Moscow (1.3%). In Moscow the results of the assay in adults were positive twice as frequently as in children, and in donors with an elevated level of alanine-transferase activity the presence of these antibodies was confirmed in 8.9% of cases. The frequency of the confirmation of the presence of anti-HCV antibodies by recombinant immunoblotting was 70.7% in all positive sera and 100% in the sera from a group of donors with an elevated enzyme level. In many respects coincidence between the regularities in the spread of viral hepatitic C and hepatitides B, D was noted.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8067143

Source DB:  PubMed          Journal:  Zh Mikrobiol Epidemiol Immunobiol        ISSN: 0372-9311


  2 in total

1.  Epidemiological and clinical aspects of hepatitis C virus infection in the Russian Republic of Daghestan.

Authors:  D T Abdourakhmanov; A S Hasaev; F J Castro; J Guardia
Journal:  Eur J Epidemiol       Date:  1998-09       Impact factor: 8.082

2.  Underreported injection drug use and its potential contribution to reported increase in sexual transmission of HIV in Kazakhstan and Kyrgyzstan.

Authors:  Anna P Deryabina; Padmaja Patnaik; Wafaa M El-Sadr
Journal:  Harm Reduct J       Date:  2019-01-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.